A feasibility study in five African sites
A case study from Bosnia and Herzegovina Eurasian Harm Reduction Network
The case study was prepared by Samir Ibisevic, President of PROI between March and June 2016 and edited by Graham Shaw.
EHRN is grateful to all who contributed to this document, especially: Dr. Serifa Godinjak, Chairperson... of Country Coordinating Mechanism; Dr. Zlatko Cardaklija, HIV Coordinator for the Federation of Bosnia and Herzegovina (BiH); Dr. Nesad Seremet, Head of the HIV program, United Nations Development Program in Bosnia and Herzegovina; Ms. Gyongyver Jakab, Fund Portfolio Manager, Eastern Europe and Central Asia and Ms. Natalya Bogach, Program Officer, The Global Fund to Fight AIDS, Tuberculosis and Malaria; Dr. Nermana Mehic–Basara, Director of the Institute for Addiction Diseases of Sarajevo Canton; Mr. Denis Dedajic, Director of the Association Margina from the Federation of BiH; Mr. Srdjan Kukolj, Director of Action Against AIDS from the Republic of Srpska.
more
The Open AIDS Journal, 2012, 6, 245-258
The limitation of a single sector approach. HNP Discussion Paper
Single TB and HIV Concept Note Albania 2016-2018 27 April 2015
The audit was undertaken in order to ascertain whether allocations and donations received directly by the Government of Sierra Leone, in the fight against the Ebola Virus Disease were utilised with due regard to economy and efficiency and that internal controls were observed accordingly. The audit f...ound that more than US$ 10 million in spending was inadequately documented and US$ 6 million may have been diverted to non-existent or “ghost” workers. The Quote: “It makes one wonder how a serious humanitarian crisis was used as money-making machine,” said Ibrahim Tommy, coordinator for Sierra Leone’s Centre for Accountability and Rule of Law
more
Available in: English, French, Chinese, Spanish, Russian, Arabic, Thai, Korean, Tajik, Vietnamese, Uzbek
http://www.who.int/disabilities/cbr/guidelines/en/
In Kenya, the bacterial infections that contribute most to human disease are often those in which re-‐sistance is most evident. Examples are multidrug-‐resistant enteric bacterial pathogens such as typhoid, ... diarrhoeagenic Escherichia coli and invasive non-‐typhi salmonella, penicillin-‐resistant Streptococcus pneu-‐moniae, vancomycin-‐resistant enterococci, methicillin-‐resistant Staphylococcus aureus and multidrug-‐re-‐sistant Mycobacterium tuberculosis. Resistance to medicines commonly used to treat malaria is of particu-‐lar concern, as is the emerging resistance to anti-‐HIV drugs. Often, more expensive medicines are required to treat these infections, and this becomes a major challenge in resource-‐poor settings.
more
Tuberculosis cases, TB deaths
Le Groupe spécial mondial de lutte contre le choléra (GTFCC) a lancé Mettre fin au choléra :
Une feuille de route mondiale pour 2030 (la Feuille de route mondiale) (1). Cette stratégie vise
à réduire de 90 % le nombre de décès dus au choléra dans le monde et à mettre fin à la
malad...ie dans au moins 20 pays d’ici 2030. Elle est organisée selon trois axes principaux :
• assurer une détection et une réponse précoces pour contenir les épidémies(2) ;
• adopter une approche multisectorielle pour prévenir et contrôler le choléra dans les
points chauds ; et
• mettre en place un mécanisme de coordination efficace de l’appui technique, la
mobilisation des ressources et des partenariats aux niveaux local et mondial.
more